Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy

Cancer Imaging

Volumn 10, Issue SPEC. ISS. A, 2010, Pages

  Hicks, R J ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

68Ga octreotate; FDG; Neuroendocrine tumour; Peptide receptor; PET; Radionuclide therapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR;

CANCER STAGING; CLASSIFICATION; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; NEUROENDOCRINE TUMOR; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

3-IODOBENZYLGUANIDINE; HUMANS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79957655847     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2010.9007     Document Type: Article

References (36)

1. Rindi G, Kloppel G. Endocrine tumors of the gut and pancreas tumor biology and classification. Neuroendocrinology 2004; 80(Suppl 1): 12-15. doi:10.1159/000080733. PMid:15477709. (Pubitemid 39382361)
2. Krenning EP, Kwekkeboom DJ, Reubi JC, et al. 111In-octreotide scintigraphy in oncology. Metabolism 1992; 41: 83-6. doi:-10.1016/0026-0495(92) 90038-C.
3. Krenning EP, Kwekkeboom DJ, Oei HY, et al. Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing-s syndrome. Digestion 1994; 55(Suppl 3): 54-9. doi:10.1159/ 000201202. PMid:7698538.
4. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9: 61-72. doi:10.1016/S1470-2045(07) 70410-2.
5. Vilar E, Salazar R, Perez-Garcia J, Cortes J, Oberg K, Tabernero J. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer 2007; 14: 221-32. doi:10.1677/ERC-06-0074. PMid:-17639039. (Pubitemid 47242624)
6. Kloppel G, Rindi G, Anlauf M, Perren A, Komminoth P. Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch 2007; 451(Suppl 1): S9-27. doi:10.1007/s00428-007-0461-0. (Pubitemid 47283382)
7. Kloppel G, Rindi G, Perren A, Komminoth P, Klimstra DS. The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Arch 2010; 456: 595-7. doi:10.1007/ s00428-010-0924-6. PMid:.
8. Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007; 451: 757-62. doi:10.1007/s00428-007-0452-1. PMid:17674042. (Pubitemid 47497934)
9. Kayani I, Bomanji JB, Groves A, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18FFDG. Cancer 2008; 112: 2447-55. doi:10.1002/cncr.23469. PMid:18383518.
10. Moertel CG, Kvols LK, O-Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227-32. doi:10.1002/ 1097-0142(19910715)68:25227::AID-CNCR28206802024-3.0.CO;2-I.
11. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010; doi:10.1245/s10434-010-1006-3.
12. Tenenbaum F, Lumbroso J, Schlumberger M, et al. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med 1995; 36: 1-6.
13. Schmidt M, Fischer E, Dietlein M, et al. Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas. Eur J Nucl Med Mol Imaging 2002; 29: 1571-80. doi:10.1007/s00259-002-0939-6. PMid:12458390.
14. Muros MA, Llamas-Elvira JM, Rodriguez A, et al. 111In-pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma. Nucl Med Commun 1998; 19: 735-42. doi:10.1097/00006231- 199808000-00003. PMid:9751927. (Pubitemid 28407504)
15. Benn DE, Richardson AL, Marsh DJ, Robinson BG. Genetic testing in pheochromocytoma-and paraganglioma-associated syndromes. Ann N Y Acad Sci 2006; 1073: 104-11. doi:10.1196/ annals.1353.011. PMid:17102077. (Pubitemid 44912003)
16. Scholz T, Schulz C, Klose S, Lehnert H. Diagnostic management of benign and malignant pheochromocytoma. Exp Clin Endocrinol Diabetes 2007; 115: 155-9. doi:10.1055/s-2007-970410. (Pubitemid 46640281)
17. Kwekkeboom DJ, van Urk H, Pauw BK, et al. Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med 1993; 34: 873-8. (Pubitemid 23174602)
18. Rockall AG, Reznek RH. Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab 2007; 21: 43-68. doi:10.1016/j.beem.2007.01. 003. (Pubitemid 46436731)
19. Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010; 31: 169-88.
20. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-63. doi:10.1200/JCO.2009.22.8510. PMid:19704057.
21. Clark OH, Benson 3rd AB, Berlin JD, et al. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Canc Netw 2009; 7: 712-47.
22. Yao JC, Hoff PM. Molecular targeted therapy for neuroendocrine tumors. Hematol Oncol Clin North Am 2007; 21: 575-81; x. doi:10.1016/j.hoc.2007.04.001. PMid:17548041. (Pubitemid 46850791)
23. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26: 3403-10. doi:10.1200/JCO.2007.15.9020. PMid:-18612155.
24. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26: 4311-8. doi:10.1200/JCO. 2008.16.-7858. PMid:18779618.
25. Eriksson B. New drugs in neuroendocrine tumors: rising of new therapeutic philosophies? Curr Opin Oncol 2010; 22: 381-6. doi:10.1097/CCO. 0b013e32833adee2. PMid:20473165.
26. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-30. doi:10.1200/JCO.2007.15. 2553. PMid:18445841.
27. Kong G, Johnston V, Ramdave S, Lau E, Rischin D, Hicks RJ. High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience. Cancer Biother Radiopharm 2009; 24: 527-33. doi:10.1089/cbr.2009.0644. PMid:19877882.
28. Bushnell Jr DL, O-Dorisio TM, O-Dorisio MS, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010; 28: 1652-9. doi:10.1200/JCO.2009.22.8585. PMid:-20194865.
29. Hubble D, Kong G, Michael M, Johnson V, Ramdave S, Hicks RJ. (177)Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity (111)In-octreotide. Eur J Nucl Med Mol Imaging 2010; doi:10.1007/s00259-010- 1483-4. PMid: 20445977.
30. Valkema R, Pauwels SA, Kvols LK, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)- octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 2005; 46(Suppl 1): 83S-91S. (Pubitemid 47619023)
31. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003; 30: 9-15. doi:10.1007/s00259-002-0982-3. PMid:12483404. (Pubitemid 36692887)
32. Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005; 46(Suppl 1): 67S-75S. (Pubitemid 47619021)
33. Forrer F, Riedweg I, Maecke HR, Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging 2008; 52: 334-40.
34. Jager PL, Chirakal R, Marriott CJ, Brouwers AH, Koopmans KP, Gulenchyn KY. 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med 2008; 49: 573-86. doi:10.2967/ jnumed.107.045708. PMid:18344441. (Pubitemid 351520605)
35. Orlefors H, Sundin A, Ahlstrom H, et al. Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors. J Clin Oncol 1998; 16: 2534-41. (Pubitemid 28309052)
36. Koopmans KP, Neels OC, Kema IP, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxyphenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 2008; 26: 1489-95. doi:10.1200/ JCO.2007.15.1126. PMid:18349401.